

## Polymeric magnetic nanoparticles for co-administration of paclitaxel and verapamil to cancer cells

F. Ahmadi<sup>1,\*</sup>, S. Mehrvarz<sup>2</sup>, A. Zargari Samadnejad<sup>2</sup>, S. Alipour<sup>1</sup>

<sup>1</sup>Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>2</sup>Student Research Committee and Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

**Background and Aims:** There has been considerable interest in developing magnetic nanoparticles as localized drug delivery carriers. Paclitaxel (PTX) is an effective chemotherapeutic agent which is used for various cancers. PTX is a substrate of cell efflux pumps and some tumors show resistance to PTX due to multi drug resistance (MDR) phenotype. Verapamil is a calcium channel blocker able to reverse the resistance caused by P-glycoprotein (P-gp). Development of a drug delivery system capable of co-administration of paclitaxel and a P-gp inhibitor to cancer cells would be valuable for overcoming drug resistance.

**Methods:** PLGA-magnetic nanoparticles (MNP) were prepared using magnetic nanoparticles and PLGA for the purpose of magnetic drug delivery. Magnetic nanoparticles of magnetite were prepared by chemical co-precipitation of ferric and ferrous chloride salts in a strong basic solution (ammonium hydroxide). PLGA-MNP containing paclitaxel and verapamil were prepared by a modified O/W emulsion solvent evaporation technique. The morphology, size, drug loading efficiency and drug release from the particles were investigated. Cell culture studies in resistant and susceptible cell lines are under development.

**Results:** Magnetic nanoparticles before encapsulation in PLGA particles were less than 100 nm in size. All MNPs were almost spherical in shape and were found to have a mean diameter within the range of 400-800 nm. Drug encapsulation efficiency of magnetic-nanoparticles was 63% for 2min sonication. MNPs were responsive to external magnetic field.

**Conclusions:** Magnetic-PLGA nanoparticles developed in this study may be used as a potential delivery system for reversion of MDR in cells resistant to PTX.

**Keywords:** Magnetic nanoparticles; Paclitaxel; Verapamil